Suraksha Diagnostic releases Q4FY26 earnings call audio for investor review

scanx
Reviewed by
Anirudha BScanX News Team
Key Highlights

Suraksha Diagnostic Limited released the audio recording of its earnings call held on August 13, 2026. The call discussed unaudited standalone and consolidated financial results for Q4FY26. The disclosure complies with SEBI LODR Regulations 30(6) and 46(2).

powered bylight_fuzz_icon
48165716

*this image is generated using AI for illustrative purposes only.

Suraksha Diagnostic has released the audio recording of its earnings call held on August 13, 2026, at 11:30 am. The session addressed the company's unaudited standalone and consolidated financial results for the quarter ended June 30, 2026 (Q4FY26), as well as broader business discussions.

The recording is accessible via the company's official website, fulfilling regulatory disclosure requirements under SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015.

Regulatory Disclosure

The intimation was issued pursuant to Regulation 30(6) and Regulation 46(2) of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015. These regulations mandate timely disclosure of material information to stock exchanges to ensure equal access to investors.

Ritu Mittal, Joint Managing Director & CEO, signed the communication. The filing was directed to the secretaries of both the Bombay Stock Exchange (BSE) and the National Stock Exchange of India (NSE).

Key Details

  • Event: Earnings Call Audio Recording Release
  • Date of Call: August 13, 2026
  • Time: 11:30 am
  • Financial Period Covered: Quarter ended June 30, 2026 (Q4FY26)
  • Results Type: Unaudited Standalone and Consolidated
  • Signatory: Ritu Mittal (Joint Managing Director & CEO)

The release ensures that institutional investors, analysts, and retail shareholders have access to the management's commentary on the financial performance for the full fiscal year 2026 and the final quarter.

Historical Stock Returns for Suraksha Diagnostic

1 Day5 Days1 Month6 Months1 Year5 Years
-0.22%+0.25%+34.68%+27.31%+12.52%0.0%

How will Suraksha Diagnostic's Q4FY26 performance influence its valuation multiples compared to key competitors in the Indian diagnostic sector?

What specific growth initiatives or capital expenditure plans did management outline for FY27 during the earnings call?

Are there any indications of margin pressure or expansion in the diagnostic services segment based on the management's commentary?

Suraksha Diagnostic Q1 Results: Net profit up 28% YoY to ₹125.8 lakh

scanx
Reviewed by
Shriram SScanX News Team
Key Highlights

Suraksha Diagnostic Ltd posted a strong Q1FY26 with standalone net profit up 27.6% YoY to ₹125.8 lakh and consolidated profit up 38.6%. Revenue grew nearly 20% across both metrics. The board appointed Dinesh Gupta as CFO and set Sept 15 as the dividend record date.

powered bylight_fuzz_icon
48097193

*this image is generated using AI for illustrative purposes only.

Suraksha Diagnostic reported a significant improvement in profitability for the quarter ended June 30, 2026, with standalone net profit rising 27.6% year-on-year to ₹125.8 lakh. The growth was underpinned by a 19.6% increase in revenue from operations to ₹840.8 lakh, outpacing the 19.2% rise in total expenses.

Consolidated figures showed even stronger momentum, with net profit attributable to owners of the parent climbing 38.6% to ₹130.0 lakh, compared to ₹93.9 lakh in Q1FY25. Consolidated revenue from operations expanded 20.7% to ₹876.4 lakh. The company’s earnings per share (basic) increased to ₹2.42 on a standalone basis and ₹2.50 on a consolidated basis, up from ₹1.89 and ₹1.80 respectively in the prior year period.

Financial Performance

The financial results reflect improved operational efficiency alongside top-line growth. While employee benefits expenses rose 11.6% to ₹138.5 lakh (standalone), other expenses grew at a faster pace of 17.6% to ₹308.4 lakh. However, the revenue growth trajectory was steeper than the cost inflation, leading to an expansion in pre-tax profit margins.

Metric Standalone Q1FY26 Standalone Q1FY25 Change Consolidated Q1FY26 Consolidated Q1FY25 Change
Revenue from Operations ₹840.8 lakh ₹702.7 lakh +19.6% ₹876.4 lakh ₹725.8 lakh +20.7%
Total Income ₹856.5 lakh ₹713.7 lakh +20.0% ₹887.3 lakh ₹734.9 lakh +20.7%
Total Expenses ₹694.3 lakh ₹582.5 lakh +19.2% ₹722.0 lakh ₹610.2 lakh +18.3%
Profit Before Tax ₹162.1 lakh ₹131.2 lakh +23.6% ₹165.2 lakh ₹124.6 lakh +32.5%
Net Profit ₹125.8 lakh ₹98.4 lakh +27.6% ₹128.4 lakh ₹91.7 lakh +39.9%

What the Numbers Show

A key observation from the filing is the divergence between standalone and consolidated performance drivers. While standalone profit grew 27.6%, consolidated profit attributed to parent owners surged 38.6%. This suggests that subsidiaries contributed disproportionately to the bottom-line improvement in this quarter, despite the holding company bearing a larger share of administrative or corporate overheads reflected in the standalone "other expenses" line item, which stood at ₹308.4 lakh versus ₹262.2 lakh in Q1FY25.

Additionally, finance costs decreased slightly in the standalone entity by 5.0% to ₹36.7 lakh, indicating potential optimization in debt servicing or interest rates, which positively impacted the pre-tax margin expansion.

Corporate Actions

During its meeting on August 12, 2026, the Board of Directors approved several key administrative decisions:

  • CFO Appointment: Mr. Dinesh Gupta has been appointed as Chief Financial Officer, effective August 24, 2026. He will also serve as Group CFO. Gupta brings over 14 years of experience, including tenures at Saranyu Power Trading, Genpact, and Maersk Global Services.
  • Dividend Record Date: Tuesday, September 15, 2026, has been fixed as the record date for determining shareholder entitlement to the FY25 dividend. Payment will be made within the statutory period following approval at the AGM.
  • AGM Notice: The revised notice for the 21st Annual General Meeting has been approved. The meeting is scheduled for Tuesday, September 22, 2026, via video conferencing/other audio-visual means (VC/OAVM).

Legal Disclosures

The company disclosed an ongoing dispute with the Government of Meghalaya involving a step-down subsidiary. As of June 30, 2026, the recoverability of investments, loans, and trade receivables aggregating to ₹393.6 lakh is under assessment. Management has provided a provision of ₹81.1 lakh on these balances on a prudent basis. Arbitration proceedings are sub judice, with the next hearing scheduled for August 21, 2026, at the High Court of Meghalaya.

Historical Stock Returns for Suraksha Diagnostic

1 Day5 Days1 Month6 Months1 Year5 Years
-0.22%+0.25%+34.68%+27.31%+12.52%0.0%

How will the appointment of Dinesh Gupta as CFO influence Suraksha Diagnostic's capital allocation strategy and debt management in the upcoming quarters?

What is the potential financial impact on the company's bottom line if the arbitration against the Government of Meghalaya results in a full recovery of the ₹393.6 lakh disputed amount?

Can the company sustain the current margin expansion trend given that 'other expenses' grew faster than employee benefits, and what measures are being taken to control these operational costs?

More News on Suraksha Diagnostic

1 Year Returns:+12.52%